Literature DB >> 10677044

Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA.

G Schilling1, J D Wood, K Duan, H H Slunt, V Gonzales, M Yamada, J K Cooper, R L Margolis, N A Jenkins, N G Copeland, H Takahashi, S Tsuji, D L Price, D R Borchelt, C A Ross.   

Abstract

Dentatorubral and pallidoluysian atrophy (DRPLA) is a member of a family of progressive neurodegenerative diseases caused by polyglutamine repeat expansion. Transgenic mice expressing full-length human atrophin-1 with 65 consecutive glutamines exhibit ataxia, tremors, abnormal movements, seizures, and premature death. These mice accumulate atrophin-1 immunoreactivity and inclusion bodies in the nuclei of multiple populations of neurons. Subcellular fractionation revealed 120 kDa nuclear fragments of mutant atrophin-1, whose abundance increased with age and phenotypic severity. Brains of DRPLA patients contained apparently identical 120 kDa nuclear fragments. By contrast, mice overexpressing atrophin-1 with 26 glutamines were phenotypically normal and did not accumulate the 120 kDa fragments. We conclude that the evolution of neuropathology in DRPLA involves proteolytic processing of mutant atrophin-1 and nuclear accumulation of truncated fragments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10677044     DOI: 10.1016/s0896-6273(00)80839-9

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  35 in total

Review 1.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

2.  Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.

Authors:  Lianwu Fu; Ya-sheng Gao; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2005-06-16       Impact factor: 5.996

Review 3.  Pathological accumulation of atrophin-1 in dentatorubralpallidoluysian atrophy.

Authors:  Yasuyo Suzuki; Ikuru Yazawa
Journal:  Int J Clin Exp Pathol       Date:  2011-04-25

4.  G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.

Authors:  Nicolas Arbez; XiaoFei He; Yong Huang; Mark Ren; Yideng Liang; Frederick C Nucifora; Xiaofang Wang; Zhong Pei; Lino Tessarolo; Wanli W Smith; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

5.  Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases.

Authors:  M Yamada; T Sato; T Shimohata; S Hayashi; S Igarashi; S Tsuji; H Takahashi
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Polyglutamine expansion alters the dynamics and molecular architecture of aggregates in dentatorubropallidoluysian atrophy.

Authors:  Justyna Hinz; Lothar Lehnhardt; Silke Zakrzewski; Gong Zhang; Zoya Ignatova
Journal:  J Biol Chem       Date:  2011-12-01       Impact factor: 5.157

Review 7.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

8.  Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk.

Authors:  Jessica E Young; Gwenn A Garden; Refugio A Martinez; Fumiaki Tanaka; C Miguel Sandoval; Annette C Smith; Bryce L Sopher; Amy Lin; Kenneth H Fischbeck; Lisa M Ellerby; Richard S Morrison; J Paul Taylor; Albert R La Spada
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

Review 9.  Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 10.  Nuclear accumulation of polyglutamine disease proteins and neuropathology.

Authors:  Lauren S Havel; Shihua Li; Xiao-Jiang Li
Journal:  Mol Brain       Date:  2009-07-03       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.